Member Profiles
Steven Marc Paul, M.D., is the Director of the Appel Alzheimer's Disease Research Institute and a Professor of Neurology (Neuroscience) and Psychiatry at the Weill Cornell Medical College. Until March 2010, he was the Executive Vice President of Science and Technology and President of the Lilly Research Laboratories (LRL) of Eli Lilly and Company. Dr. Paul joined Lilly in April of 1993, initially as a Vice President of the Lilly Research Laboratories responsible for Central Nervous System (CNS) Discovery and Decision Phase Medical Research. In 1996, Dr. Paul was appointed Vice President (and in 1998 Group Vice President) of Therapeutic Area Discovery Research and Clinical Investigation. In this position his responsibilities included all therapeutic area discovery research, medicinal chemistry, toxicology/drug disposition, and decision phase (phase I/II) medical research. He and his leadership team were responsible for meeting the pipeline performance objectives of LRL and improving R&D productivity especially in discovery and the early phases of clinical development. In 2003, Dr. Paul was named Executive Vice President of the Company and President of LRL with responsibility for all research and development at Lilly. In 2005, Dr. Paul was named Chief Scientific Officer of the Year as one of the Annual Pharmaceutical Achievement Awards. Prior to assuming his position at Lilly, Dr. Paul served as Scientific Director of the National Institute of Mental Health (NIMH/NIH) in Bethesda, Maryland.
Dr. Paul received his Bachelor of Arts degree, Magna Cum Laude with honors in Biology and Psychology from Tulane University, in 1972. He received his Master of Science degree in Anatomy (Neuroanatomy) and his Doctor of Medicine degree, both in 1975, from the Tulane University School of Medicine. Following an internship in Neurology at Charity Hospital in New Orleans, he served as a resident in Psychiatry and an Instructor in the Department of Psychiatry at the University of Chicago, Pritzker School of Medicine. In 1976, he was awarded a research fellowship in the Pharmacology Research Associate Training Program of the National Institute of General Medical Science (NIGMS), to work with Nobel Laureate Dr. Julius Axelrod in the Laboratory of Clinical Science, IRP, of the NIMH. In June 1978, he became a Clinical Associate in the Clinical Psychobiology Branch of NIMH, and served in that position for two years. In 1982, Dr. Paul was appointed Chief of the Clinical Neuroscience Branch as well as Chief of the Section on Preclinical Studies, IRP, NIMH. Dr. Paul also served as Medical Director in the Commissioned Corps of the United States Public Health Service, and maintained a private practice in Psychiatry and Psychopharmacology. He is Board Certified by the American Board of Psychiatry and Neurology and has been elected a Fellow in the American College of Neuropsychopharmacology (ACNP), served on the ACNP Council and was elected President of the ACNP (1999). Dr. Paul is currently licensed to practice medicine in the State of Maryland. He also serves on the executive board of PhRMA’s Science and Regulatory Committee and is incoming chairperson. Dr. Paul served as a member of the National Advisory General Medical Sciences Council, NIH (1996-1999), and was appointed by the Secretary of HHS to serve as a member of the Advisory Committee to the Director of NIH (2001-2006).